Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Bullboard Posts
Post by LEOTHELIONon May 16, 2017 10:34pm
96 Views
Post# 26253017

Purpose of Tripp's call?

Purpose of Tripp's call?Curious to find out the purpose of Tripp's scheduled conference call this coming Thursday. Is this a promotional exercise to get the word out there about IDL being up and running in order to help generate more testing? Is this a platform to announce a new collaboration? Will he simply highlight the speaking points from last quarter's release? I would bet he will speak to Breastsentry and it's availability. He says that this conference call is in response to investor and media inquiries regarding operation and partnership activities. Well, it's obvious that investors want to know the rate of testing ramp up? This question AND cash flow/burn rate must be the most obvious on the minds of investors... Tripp must know this. So will he answer these questions? If it's just a publicity stunt to buy him some more time, that certainly will not be well received. Time to be clear and to the point James! We would like current results and realistic projections. Otherwise, no point in holding this call.
Bullboard Posts